Treatment of Ophthalmic Shingles (Herpes Zoster Ophthalmicus)
Initiate oral antiviral therapy immediately upon clinical suspicion of ophthalmic shingles, ideally within 72 hours of rash onset, using valacyclovir 1000 mg three times daily for 7 days, famciclovir 500 mg three times daily for 7 days, or acyclovir 800 mg five times daily for 7 days. 1
Immediate Management
Oral Antiviral Therapy (First-Line Treatment)
The cornerstone of treatment is systemic antiviral therapy, which is most effective when started within 72 hours of rash onset but should be initiated even if this window has passed 2. The recommended regimens for immunocompetent patients include 1:
- Valacyclovir: 1000 mg every 8 hours for 7 days
- Famciclovir: 500 mg three times daily for 7 days
- Acyclovir: 800 mg five times daily for 7 days
These oral antivirals prevent progression of disease, reduce ocular complications, and decrease the risk of vision-threatening sequelae 3, 2.
When to Add Topical Therapy
Topical antivirals alone are not effective for VZV conjunctivitis but may be used as adjunctive treatment in unresponsive cases 1. Topical antibiotics should be applied to prevent secondary bacterial infection of vesicular lesions on the eyelids, as these undergo necrosis before healing and can lead to severe conjunctival scarring or cicatricial ectropion 1.
Critical Warning About Corticosteroids
Avoid topical corticosteroids during acute epithelial disease, as they can potentiate viral replication 1. Corticosteroids may be considered only for stromal keratitis or uveitis, and must be used in conjunction with antiviral therapy 1.
Special Populations Requiring Modified Treatment
Immunocompromised Patients
Immunocompromised patients require more aggressive treatment 1:
- Consider higher doses or prolonged duration of oral antivirals
- May require IV acyclovir for severe disease 1
- Monitor closely for uncommon manifestations like acute retinal necrosis (ARN), which occurs significantly more frequently in this population (odds ratio 4.55) 4
- Exercise caution with renal dose adjustments 1
Patients with Chronic or Recurrent Disease
For persistent or recalcitrant disease, patients may require 1:
- Prolonged treatment with dose adjustment based on clinical response
- Long-term prophylaxis with lower-dose antivirals
- A recent high-quality randomized trial showed that suppressive valacyclovir 1000 mg daily for 12 months reduced multiple episodes of keratitis or iritis at both 12 months (HR 0.70) and 18 months (HR 0.72), though the primary endpoint at 12 months did not reach statistical significance 5
Mandatory Ophthalmology Consultation
Urgent ophthalmology referral is required for all suspected cases of ophthalmic shingles 3, 6. Approximately 50% of HZO patients develop ocular complications, with up to 25% experiencing chronic or recurrent disease 3. Vision-threatening complications include:
- Keratitis (stromal, epithelial, or pseudodendritic) 1
- Anterior uveitis/iritis 1
- Corneal scarring and neovascularization 1
- Acute retinal necrosis (particularly in immunosuppressed patients) 4
- Secondary glaucoma 1
- Optic neuropathy 3, 7
Follow-Up Protocol
Initial Follow-Up (Within 1 Week)
Schedule follow-up within 1 week to assess 1:
- Interval history
- Visual acuity measurement
- Slit-lamp biomicroscopy
- Response to antiviral therapy
Monitoring for Subepithelial Infiltrates
Evaluate for corneal subepithelial infiltrates, which typically develop 1 or more weeks after conjunctivitis onset 1:
- Mild cases: Observation is sufficient
- Symptomatic cases (blurring, photophobia, decreased vision): Consider minimum effective dose of topical corticosteroids (fluorometholone or loteprednol preferred to minimize IOP elevation and cataract risk) 1
- Alternative: Cyclosporine drops 0.05% to 1% have shown benefit for reducing subepithelial infiltrates 1
Long-Term Monitoring
For patients on topical corticosteroids, conduct regular follow-up including 1:
- Interval history
- Visual acuity and IOP measurement
- Slit-lamp biomicroscopy
- Slow taper to minimum effective dose once inflammation is controlled
Late Sequelae to Monitor
Be vigilant for chronic complications that may develop months after acute infection 1:
- Dry eye syndrome
- Corneal anesthesia with neurotrophic keratitis
- Chronic ocular inflammation
- Postherpetic neuralgia (may require systemic neuropathic pain management with tricyclic antidepressants or anticonvulsants) 1
Prevention
Vaccination is the most effective strategy to prevent HZO and its complications 1, 3. The recombinant zoster vaccine (RZV/Shingrix) is more effective than the live-attenuated vaccine (ZVL/Zostavax) and is recommended for 1:
- Adults aged 50 years and older
- Adults aged 18 years and older who are immunocompromised
The frequency of HZO has shown a consistent increase of 2.9% annually from 2012 to 2021, though a 5.1% decrease was observed from 2008 to 2012 in patients aged 60 and older following live zoster vaccine availability 4.